Drugs Made In America Acquisition (DMAA) Shares Outstanding (Diluted Average) (2024 - 2025)

Drugs Made In America Acquisition (DMAA) reported Shares Outstanding (Diluted Average) of $21.0 million for Q4 2025, up 145.1% on a YoY basis from $8.6 million in Q4 2024, and up 3.3% quarter-over-quarter from $20.3 million in Q3 2025.

Drugs Made In America Acquisition (DMAA) Shares Outstanding (Diluted Average) (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition has reported Shares Outstanding (Diluted Average) for 2 years, with the latest figure at $21.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 145.1% year-over-year to $21.0 million; the trailing twelve-month figure through Dec 2025 stood at $21.0 million (up 145.1% YoY), and the FY2025 full-year result was $21.0 million, up 145.1% from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 stood at $21.0 million, up from $20.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $21.0 million in Q4 2025, with the low at $8.6 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Diluted Avg.) (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - 46.95 Mn
2 Berto Acquisition 312.46 Mn 312.46 Mn - 7.50 Mn
3 Centurion Acquisition 311.65 Mn 311.65 Mn - -
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn - 28.75 Mn
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - 7.91 Mn
6 WEN Acquisition 309.15 Mn 309.15 Mn - 19.27 Mn
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn - 25.80 Mn
8 Soulpower Acquisition 264.91 Mn 264.91 Mn - 25.62 Mn
9 BTC Development 262.16 Mn 262.16 Mn - 26.06 Mn
10 Drugs Made In America Acquisition 223.11 Mn 223.11 Mn - 21.01 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 21.01 Mn
Sep 30, 2025 20.34 Mn
Jun 30, 2025 19.11 Mn
Mar 31, 2025 10.33 Mn
Dec 31, 2024 8.57 Mn